HYPOLIPIDEMIC AND PLEIOTROPIC EFFICACY OF ROSUVASTATIN IN ARTERIAL HYPERTENSION PATIENTS OF HIGH CARDIOVASCULAR RISK IN LONG-TERM OUTPATIENT FOLLOW-UP

• Main Authors: V. P. Mikhin, Yu. A. Zhilyaeva, V. V. Vorotyntseva, D. V. Nebieridze, N. M. Akhmedzhanov, D. A. Vasil’eva, M. A. Chernyatina, N. A. Gromnatsky
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2016-12-01
• Series: Российский кардиологический журнал
• Subjects: atherosclerosis; hypercholesterolemia; statins; rosuvastatin; endothelial dysfunction; vessel wall stiffness; cardiovascular risk
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/992
• ISSN: 1560-4071; 2618-7620

Aim. To evaluate the pleiotropical and hypolipidepmic efficacy of generic rosuvastatin (Rosucard) comparing with atorvastatin in arterial hypertension patients (AH) with high and very high cardiovascular risk (CVR) during the long-term usage in outpatient circumstances. Material and methods. Totally, 114 patients studied (age 58,2±3,11 y. o.) with AH of II-III grades and with high or very high CVR by SCORE, taking antihypertension treatment with metoprolol, indapaminde, enalapril in effective dosages, who, during the previous 1 year of atorvastatin treatment (20 mg/day) did not reach the target level of cholesterol. Atorvastatin was replaced by rosuvastatin 10 mg/day for 1,5 year. If the mentioned dosage did not reach cholesterol and low-density lipoproteides (CLDL) to target levels by 6 weeks, dosage was increased to 20 mg/day, and then if again not achieved during next 6 weeks, to 40 mg/day.Results. Introduction of rosuvastatin to the complex treatment was followed by further decrease of atherogenic lipids: cholesterol by 24%, CLDL by 53% and was followed with the decrease of vessel wall stiffness — decreased CAVI by 12%, augmentation index by 17%, improvement of the vasodilation endothelium function by 24%.Conclusion. Rosucard has, together with hypolipidemic properties, the pleiotropic properties more prominent than in atorvastatin, that makes it to apply the drug in AH patients with high and very high CVR for prevention of cardiovascular complications in outpatient practice.